About this trial
The goal of this clinical trial is to evaluate the efficacy of screening for liver disease with liver stiffness measurement on abstinence or light consumption after 6 months in individuals who are receiving treatment for alcohol use disorder and without a history of liver disease. The investigators will conduct a randomized controlled trial with concealed allocation comparing A) an invitation to a liver stiffness measurement, blood sampling and leaflet on alcohol-related disease (intervention) with B) an invitation to blood sampling (control). The primary outcome is 'abstinence or light consumption' (≤ 10 units/week) throughout the last months, and assessed 6 months after randomization.
Eligibility criteria
Qualifiers
Attending outpatient treatment for alcohol use disorder (international classification of disease version 10: F102: alcohol dependence or F101: harmful alcohol use) at Novavi Køge or Novavi Roskilde
Informed written consent
Disqualifiers
Not speaking Danish or English
Severe liver disease (known by the participant)
Trial design
Treatments tested in this trial
- Transient Elastography
Treatment groups
Sponsors and collaborators
Zealand University Hospital
Lead sponsor
Novavi
Collaborator
Aarhus University Hospital
Collaborator
Frederiksberg University Hospital
Collaborator
University of Copenhagen
Collaborator